LA
INTS icon

Legacy Advisors’s Intensity Therapeutics INTS Stock Holding History

Legacy Advisors’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,138
Closed -$62.9K – 297
2025
Q4 		$62.9K Buy
+6,138
New +$62.2K 0.01% 283

Other funds holding INTS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.18B AUM 18.43% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Legacy Advisors's INTS Position: Q1 2026 in Review

Legacy Advisors sold out of Intensity Therapeutics (INTS) in Q1 2026, closing a stake of 6,138 shares — an estimated $62.9K sold.

Legacy Advisors first reported a position in INTS in Q4 2025 and held it in 1 quarter. The position peaked at $62.9K in Q4 2025. 13 funds tracked by Wall St. Rank hold INTS as of Q1 2026.

  • Legacy Advisors reported no remaining Intensity Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Legacy Advisors sold 6,138 Intensity Therapeutics shares in Q1 2026, an estimated $62.9K.
  • Legacy Advisors first reported a position in Intensity Therapeutics in Q4 2025 and held it in 1 quarter.
  • Legacy Advisors's Intensity Therapeutics position peaked at $62.9K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q1 2026.

Based on Legacy Advisors's 13F filing for Q1 2026, filed 5 May 2026.